MARKET

LPTX

LPTX

LEAP THERAPEUTIC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.840
+0.010
+0.35%
After Hours: 2.840 0 0.00% 19:55 01/14 EST
OPEN
2.760
PREV CLOSE
2.830
HIGH
2.850
LOW
2.680
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
4.170
52 WEEK LOW
1.330
MARKET CAP
250.82M
P/E (TTM)
-5.0035
1D
5D
1M
3M
1Y
5Y
Hedge Funds Are Crazy About LEAP THERAPEUTICS, INC. (LPTX)
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds...
Insider Monkey · 4d ago
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wain...
PR Newswire · 01/05 12:00
Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 40th Annu...
PR Newswire · 01/03 12:00
Leap Therapeutics (NASDAQ:LPTX) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 12/10/2021 11:59
BRIEF-Leap Secures Strategic Funding From Japan Energy Fund
reuters.com · 12/02/2021 14:15
Tang Capital Management Llc Buys ITeos Therapeutics Inc, Corvus Pharmaceuticals Inc, aTyr ...
GuruFocus News · 11/16/2021 22:38
Ally Bridge Group (NY) LLC Buys SomaLogic Inc, Rapid Micro Biosystems Inc, Sight Sciences Inc, ...
GuruFocus News · 11/15/2021 15:38
Leap Therapeutics reports Q3 results
Leap Therapeutics (NASDAQ:LPTX): Q3 GAAP EPS of -$0.92. Cash, cash equivalents and marketable debt securities totaling $78M Press Release
Seekingalpha · 11/12/2021 12:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LPTX. Analyze the recent business situations of LEAP THERAPEUTIC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LPTX stock price target is 4.800 with a high estimate of 6.00 and a low estimate of 4.000.
High6.00
Average4.800
Low4.000
Current 2.840
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 83
Institutional Holdings: 47.38M
% Owned: 53.64%
Shares Outstanding: 88.32M
TypeInstitutionsShares
Increased
16
3.91M
New
32
20.43M
Decreased
7
229.72K
Sold Out
8
3.84M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Director
Christopher Mirabelli
President/Chief Executive Officer/Director
Douglas Onsi
Chief Operating Officer
Augustine Lawlor
Vice President
Christine Granfield
Other
Mark O'Mahony
Other
Cynthia Sirard
Lead Director/Independent Director
Thomas Dietz
Independent Director
Monica Bertagnolli
Independent Director
James Cavanaugh
Independent Director
William Li
Independent Director
Joseph Loscalzo
Independent Director
Nissim Mashiach
No Data
About LPTX
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.

Webull offers kinds of Leap Therapeutics Inc stock information, including NASDAQ:LPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPTX stock methods without spending real money on the virtual paper trading platform.